Purification, characterization, and drug susceptibility of tubulin from Leishmania

Molecular and Biochemical Parasitology

Volumn 98, Issue 1, 1999, Pages 53-65

  Werbovetz, Karl A ^a   Brendle, James J ^a   Sackett, Dan L ^b  

^a Div Exp Therapeut   (United States)

^b Res Devmt Devmtl Therapeut P   (United States)

Author keywords

Drug discovery; Leishmania; Tubulin

Indexed keywords

4 CHLORO 3,5 DINITROBENZOTRIFLUORIDE; ARSENOSOBENZENE; COLCHICINE; MAYTANSINE; RHIZOXIN; STIBOGLUCONATE SODIUM; TRIFLURALIN; TUBULIN; UNCLASSIFIED DRUG; VINBLASTINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; IMMUNOBLOTTING; LEISHMANIA MEXICANA; MICROTUBULE ASSEMBLY; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; PROTEIN PURIFICATION;

ANIMALS; ANTIPROTOZOAL AGENTS; ARSENICALS; BINDING SITES; DINITROCHLOROBENZENE; LEISHMANIA; LEISHMANIA DONOVANI; LEISHMANIA MEXICANA; MAYTANSINE; PACLITAXEL; PROTOZOAN PROTEINS; RATS; SPECIES SPECIFICITY; TRIFLURALIN; TUBULIN;

LEISHMANIA AMAZONENSIS; LEISHMANIA DONOVANI; LEISHMANIA MEXICANA; VINCA;

EID: 0032929522     PISSN: 01666851     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-6851(98)00146-7     Document Type: Article

References (41)

1. Berman J. Human leishmaniasis: clinical; diagnostic; and chemotherapeutic developments in the last 10 years. Clin. Infect. Dis. 24:1997;684-703.
2. Werbovetz K., Jeronimo S., Macdonald T., Pearson R. Treatment of leishmaniasis and trypanosomiasis. Curr. Opin. Infect. Dis. 5:1992;840-848.
3. Momen H. Emerging infectious diseases: Brazil. Emerg. Infect. Dis. 4:1998;1-3.
4. Fong D., Chang K. Tubulin biosynthesis in the developmental cycle of a parasitic protozoan, Leishmania mexicana: changes during differentiation of motile and nonmotile stages. Proc. Natl. Acad. Sci. USA. 78:1981;7624-7628.
5. MacRae T., Gull K. Purification and assembly in vitro of tubulin from Trypanosoma brucei brucei. Biochem. J. 265:1990;87-93.
6. Russell D., Gull K. Tubulin heterogeneity in the trypanosome Crithidia fasciculata. Mol. Cell. Biol. 4:1984;779-790.
7. Schneider A., Sherwin T., Sasse R., Russell D., Gull K., Seebeck T. Subpellicular and flagellar microtubules of Trypanosoma brucei brucei contain the same α-tubulin isoforms. J. Cell. Biol. 104:1987;431-438.
8. Baum S., Wittner M., Nadler J., Horwitz S., Dennis J., Schiff P., Tanowitz H. Taxol, a microtubule stabilizing agent, blocks the replication of Trypanosoma cruzi. Proc. Natl. Acad. Sci. USA. 78:1981;4571-4575.
9. Moulay L., Robert-Gero M., Brown S., Gendron M., Tournier F. Sinefungin and taxcl effects on cell cycle and cytoskeleton of Leishmania donovani promastigotes. Exp. Cell. Res. 226:1996;283-291.
10. Robinson D., Sherwin T., Ploubidou A., Byard E., Gull K. Microtubule polarity and dynamics in the control of organelle positioning, segregation, and cytokinesis in the trypanosome cell cycle. J. Cell. Biol. 128:1995;1163-1172.
11. Ersfeld K., Gull K. Partitioning of large and minichromosomes in Trypanosoma brucei. Science. 276:1997;611-614.
12. Chan M., Fong D. Inhibition of Leishmanias but not host macrophages by the antitubulin herbicide trifluralin. Science. 249:1990;924-926.
13. Callahan H., Kelley C., Pereira T., Grogl M. Microtubule inhibitors: structure activity analyses suggest rational models to identify potentially active compounds. Antimicrob. Agents. Chemother. 40:1996;947-952.
14. Bai R., Duanmu C., Hamel E. Mechanism of action of the antimitotic drug 2,4 dichlorobenzyl thiocyanate: alkylation of sulfhydryl group(s) of β-tubulin. Biochim. Biophys. Acta. 994:1989;12-20.
15. Russell D., Dubremetz J. Microtubular cytoskeletons of parasitic protozoa. Parasitol. Today. 2:1986;177-179.
16. Katiyar S., Gordon V., McLaughlin G., Edlind T. Antiprotozoal activities of benzimidazoles and correlations with beta-tubulin sequence. Antimicrob. Agents. Chemother. 38:1994;2086-2090.
17. Joshi M., Dwyer D., Nakhasi H. Cloning and characterization of differentially expressed genes from in vitro-grown 'amastigotes' of Leishmania donovani. Mol. Biochem. Parasitol. 58:1993;345-354.
18. Sackett D., Knipling L., Wolff J. Isolation of microtubule protein from mammalian brain frozen for extended periods of time. Prot. Express. Purif. 2:1991;390-393.
19. Sackett D. Vinca site agents induce structural changes in tubulin different from and antagonistic to changes induced by colchicine site agents. Biochemistry. 34:1995;7010-7019.
20. Luduena R., Roach M. Tubulin auflhydryl groups as probes and targets for antimitotic and antimicrotubule agents. Pharmacol. Ther. 49:1991;133-152.
21. Schmitt H., Kram R. Binding of antimitotic drugs around cysteine residues of tubulin. Exp. Cell. Res. 115:1978;408-411.
22. Blokhin A., Yoo H., Geralds R., Nagle D., Gerwick W., Hamel E. Characterization of the interaction of the marine cyanobacterial natural product curacin A with the colchicine site of tubulin and initial structure-activity studies with analogues. Mol. Pharmacol. 48:1995;523-531.
23. Bai R., Pettit G., Hamel E. Dolastatin 10; a powerful cytostatic peptide derived from a marine animal. Biochem. Pharmacol. 39:1990;1941-1949.
24. Takahashi M., Iwasaki S., Kobayashi H., Okuda S. Studies on macrocyclic lactone antibiotics XI. Anti-mitotic and anti-tubulin activity of new antitumor antibiotics; rhizoxin and its homologues. J. Antibiotics. 40:1987;66-72.
25. Sereno D., Lemesre J. Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Antimicrob. Agents. Chemother. 41:1997;972-976.
26. Berg K., Zhai L., Kharazmi A., Owen T.C. The use of a water-soluble formazan complex to quantitate the cell number and mitochondrial function of Leishmania major promastigotes. Parasitol. Res. 80:1994;235-239.
27. Callahan H., Portal A., Deveraux R., Grogl M. An axenic amastigote system for drug screening. Antimicrob. Agents. Chemother. 41:1997;818-822.
28. Seebeck T., Hemphill A., Lawson D. The cytoskeleton of trypanosomes. Parasitol. Today. 6:1990;49-52.
29. Sherwin T., Gull K. The cell division cycle of Trypanosoma brucei brucei: Timing of event markers and cytoskeletal modulations. Phil. Trans. R. Society. of. London. B323:1989;573-588.
30. Hamel E., del Campo A., Lin C. Microtubule assembly with the guanosine 5′ diphosphate analogue 2,3′-dideoxyguanosine 5′-diphosphate. Biochemistry. 22:1983;3664-3671.
31. Robinson D., Gull K. Basal body movements as a mechanism for mitochondrial genome segregation in the trypanosome cell cycle. Nature. 352:1991;731-733.
32. Chow L., Wong A., Ullman B., Wirth D. Cloning and functional analysis of an extrachromosomally amplified multidrug resistance-like gene in Leishmania enrietti. Mol. Biochem. Parasitol. 60:1993;195-208.
33. Jordan M., Thrower D., Wilson L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer. Res. 51:1991;2212-2222.
34. van Veen H., Callaghan R., Soceneantu L., Sardini A., Konings W., Higgins C. A bacterial antibiotic-resistance gene that complements the human multidrug-resistance P glycoprotein gene. Nature. 391:1998;291-295.
35. Lee Y., Yaple R., Baldridge R., Kirsch M., Himes R. Inhibition of tubulin self assembly in vitro by fluorodinitrobenzene. Biochim. Biophys. Acta. 671:1981;71-77.
36. Mottram J., Coombs G. Leishmania mexicana: enzyme activities of amastigotes and promastigotes and their inhibition by antimonials and arsenicals. Exp. Parasitol. 59:1985;151-160.
37. Fairlamb A., Henderson G., Cerami A. Trypanothione is the primary target for arsenical drugs against African trypanosomes. Proc. Natl. Acad. Sci. USA. 86:1989;2607-2611.
38. Cunningham M., Zvelebil M., Fairlamb A. Mechanism of inhibition of trypanothione reductase and glutathione reductase by trivalent organic arsenicals. Eur. J. Biochem. 221:1994;285-295.
39. Ramirez P., Eastmond D., Laclette J., Ostrosk-Wegman P. Disruption of microtubule assembly and spindle formation as a mechanism for the induction of aneuploid cells by sodium arsenite and vanadium pentoxide. Mutation. Res. 386:1997;291-298.
40. Lin C., Singh S., Chu P., Dempcy R., Schmidt J., Pettit G., Hamel E. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol. Pharmacol. 34:1988;200-208.
41. Pettit G., Singh S., Niven M., Hamel E., Schmidt J. Isolation; structure and synthesis of combretastatins A-1 and B-1; potent new inhibitors of microtubule assembly; derived from Combretum caffrum. J. Nat. Prod. 50:1987;119-131.